PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Science. Author manuscript; available in PMC May 10, 2010.
Published in final edited form as:
PMCID: PMC2866193
NIHMSID: NIHMS191376
Differential Regulation of Dynein and Kinesin Motor Proteins by Tau
Ram Dixit,1 Jennifer L. Ross,2 Yale E. Goldman,1 and Erika L. F. Holzbaur1*
1 Department of Physiology and Pennsylvania Muscle Institute, University of Pennsylvania, Philadelphia, PA 19104. USA
* To whom correspondence should be addressed. holzbaur/at/mail.med.upenn.edu
2Current address: 302 Hasbrouck Laboratory, Department of Physics, University of Massachusetts at Amherst, Amherst, MA 01003. USA
Dynein and kinesin motor proteins transport cellular cargos toward opposite ends of microtubule tracks. In neurons, microtubules are abundantly decorated with microtubule-associated proteins (MAPs) such as tau. Motor proteins thus encounter MAPs frequently along their path. To determine the effects of tau on dynein and kinesin motility, we conducted single molecule studies of motor proteins moving along tau-decorated microtubules. Dynein tended to reverse direction whereas kinesin tended to detach at patches of bound tau. Kinesin was inhibited at ~ 10-fold lower tau concentration than dynein and the microtubule-binding domain of tau was sufficient to inhibit motor activity. The differential modulation of dynein and kinesin motility suggests that MAPs can spatially regulate the balance of microtubule-dependent axonal transport.
Active transport of cytoplasmic material along microtubules is critical for cell organization and function, and defects in this process are associated with dysfunction and disease (1). Much of the active transport in cells depends on the molecular motor proteins cytoplasmic dynein and kinesin-1, which transport cargo toward the minus-end (toward the cell center) and plus-end of microtubules (toward the cell periphery), respectively. Dynein and kinesin have very different structures and translocation mechanisms (2). Kinesin has a compact motor domain and walks unidirectionally along single protofilaments with 8-nm steps (2). In contrast, dynein has a larger, more complex motor domain and is capable of variable step sizes, lateral steps across the microtubule surface, and processive runs toward both the minus- and plus-end of the microtubule (35). Cytoplasmic dynein function in vivo also requires an accessory complex, dynactin. This large, multiprotein complex is thought to facilitate dynein processivity (6) and may also regulate dynein activity (5). Within the cell, the balance between oppositely directed transport determines the steady-state distribution of organelles and biomolecules.
In the crowded cell environment, dynein and kinesin compete with non-motile microtubule-associated proteins (MAPs) for binding to the microtubule surface. MAPs bound to microtubules might also block the path of motor proteins. Thus, MAPs can provide spatiotemporal regulation of motor proteins in vivo. Tau, a neuronal MAP, inhibits kinesin activity in vivo and in vitro (710); however, its effect on dynein activity is not well understood. Our aim was to directly observe individual encounters between single dynein or kinesin motors and tau on microtubule tracks to determine how structurally distinct motors respond to obstacles in their path.
Tau is expressed in neurons as multiple splice forms in a developmentally regulated manner (11). These isoforms differ in the number of microtubule binding repeats and the length of the projection domain (Fig. 1A). Here we focused on the shortest and longest tau isoforms, tau23 and tau40, to compare their overall effects on motor proteins. To directly visualize tau on microtubules, we fluorescently tagged purified recombinant tau proteins with Alexa 546 dye (Fig. S1A). Functionality of labeled tau was demonstrated in microtubule binding assays (Fig. S2).
Fig. 1
Fig. 1
Decoration of microtubules by Alexa-labeled tau. (A) Tau structure consists of an acidic projection domain and a basic microtubule-binding domain containing microtubule-binding repeats (R1–R4) and proline-rich regions (P1–P3). In the mammalian (more ...)
Alexa-labeled tau23 and tau40 decorated taxol-stabilized microtubules in patches whose size and fluorescence intensity increased with tau concentration (Fig. 1B). At 10 nM tau, patches were composed of 3 to 20 labeled tau molecules. Analysis of the spatial frequency spectrum of fluorescence intensity along the microtubule suggested that tau patches typically extended up to 1.2 μm (see legend to Fig. S4). At peak intensity within a patch, we observed 4–5 bleaching events (Fig. 1C), corresponding to ~ 10 total tau molecules per diffraction limited spot. These patches were formed by stepwise association of single tau molecules (Fig. 1D), consistent with tau’s property to self-associate into clusters along the microtubule surface (12). The low ionic strength buffer used in our experiments may facilitate tau clustering; but concentration-dependent tau clustering has also been observed along axons in cultured neurons (13). Under the conditions of our experiments, the Alexa-tau patches were stable over the time course of several minutes (Fig. 1E), significantly longer than the average duration of motor runs (5–30 s). This feature allowed the direct visualization of encounters between motors and tau molecules bound to the microtubule surface.
Interactions between green fluorescent protein (GFP)-labeled dynein-dynactin isolated from mouse brain (5) or recombinant kinesin-GFP (14) (Fig. S1B and C) and Alexa-labeled tau on microtubules were observed directly by total internal reflection fluorescence (TIRF) microscopy (5). The frequency of kinesin-GFP binding to microtubules decreased with increasing local tau fluorescence intensity; whereas, the frequency of dynein-dynactin-GFP binding was nearly independent of local tau fluorescence intensity (Fig. S3). Thus, kinesin-GFP binding was inhibited more effectively by tau than dynein-dynactin-GFP binding.
When single kinesin-GFP motors encountered tau patches on the microtubule, the majority of motors detached from the microtubule surface (Fig. 2A and B and Movies S1 and S2). For a given tau patch, kinesin was likely to detach at the position of peak tau fluorescence intensity (Fig. 2B). Hence, the probability of kinesin detachment is a function of the local tau concentration. Inhibition of kinesin motility was also tau isoform-specific. When kinesin-GFP did bind within a tau23 patch, mean run length was reduced by ~ 50% compared to mean run length along bare microtubule regions (from 1.7 ±0.25 μm to 0.9 ±0.03 μm; n ≥ 100). While tau40 patches also induced detachment of kinesin-GFP molecules (Fig. 2A and Movie S2), the mean run length of kinesin-GFP moving within tau40 patches was not affected significantly (1.89 ±0.36 μm; n = 51).
Fig. 2
Fig. 2
Direct observation of encounters between single molecules of kinesin or dynein-dynactin and Alexa-labeled tau. (A) The effect of Alexa-tau23 (red bars) and Alexa-tau40 (blue bars) on kinesin and dynein motility. Kinesin either detaches, passes or pauses (more ...)
In contrast to kinesin, encounters of dynein-dynactin-GFP with Alexa-tau molecules did not induce motor detachment or pausing. Instead, dynein-dynactin tended to reverse direction upon encountering tau (Fig. 2A and C and Movies S3 and S4). When dynein-dynactin bound within a tau23 patch, it did not rapidly detach like kinesin, but remained paused for relatively long periods (3–15 s). Tau40 also induced directional reversals as dynein-dynactin approached tau patches (Fig. 2A), however, the velocity and run length of dynein-dynactin within an Alexa-tau40 patch were not affected significantly (Movie S4).
Thus dynein-dynactin’s response to encounters with tau was fundamentally different from kinesin’s response, which may be related to dynein-dynactin’s innate ability to execute processive backward runs. This ability would allow dynein-dynactin to remain attached to the microtubule following encounters with tau; whereas, kinesin’s inflexible nature makes it more likely to detach from the microtubule.
To examine the concentration-dependent effect of tau on motor function, we varied unlabeled tau23 and tau40 over a range encompassing the normal endogenous molar ratio of tubulin:tau of ~ 20:1. Tau decreased the binding frequency, motile fraction (defined as the proportion of landing motors that moved ≥250 nm) and run length of both kinesin-GFP and dynein-dynactin-GFP in a concentration- and isoform-dependent manner (Fig. 3A and B; Movies S5S10). The inhibitory effects of tau23 were less pronounced for dynein-dynactin than for kinesin. For example, 1 nM tau23 (50:1 tubulin:tau molar ratio) inhibited significantly the binding frequency and run length of kinesin but not of dynein-dynactin (Fig. 3). Significant inhibition of dynein was not observed until tau23 concentration was raised 10-fold. Tau40 was a less potent inhibitor for both motors; we did not obtain significant inhibition of either kinesin or dynein-dynactin motility at physiologically relevant tubulin:tau molar ratios with this isoform (Fig. 3). Neither tau23 nor tau40 significantly changed motor velocity of either kinesin or dynein-dynactin at any of the concentrations tested (Table S1).
Fig. 3
Fig. 3
Concentration- and isoform-dependent effect of tau on kinesin and dynein-dynactin motility. (A) Representative kymographs show kinesin and dynein-dynactin motility at 0 nM tau23 and at 10 nM tau23. x-scale bar = 1 μm; y-scale bar = 5 s. The bar (more ...)
From a structural standpoint, tau might inhibit motor function through its projection domain and/or its microtubule-binding domain. To determine the relative contribution of these domains to motor inhibition, we studied the effects of truncated versions of tau23 on motor function. The truncated polypeptides, designated K35 and K33, differ in the length of their projection domain (Fig. 1A) but have similar microtubule binding affinities to that of full-length tau23 (15). Alexa-labeled K35 and K33 decorated microtubules in a pattern similar to that observed for Alexa-labeled tau23 (Fig. S4). The truncated forms of tau inhibited both kinesin-GFP and dynein-dynactin-GFP in a concentration-dependent manner (Fig. 4A). In fact, both truncated forms were stronger inhibitors of motor proteins than full-length tau23. Thus the microtubule-binding domain of tau was sufficient for motor inhibition. Differences in the net charge of the projection domain between tau40 (−15), tau23 (−4) and K35 (+5) correlate well with their relative ability to inhibit binding of motor proteins, suggesting that the acidic projection domain may mimic the acidic tail of tubulin and electrostatically recruit motor proteins to the microtubule surface.
Fig. 4
Fig. 4
Comparison of the inhibitory effect of full-length and truncated versions of tau23 on kinesin and dynein-dynactin motility. (A) The bar graphs illustrate the effect of 0 nM (yellow bars), 10 nM (orange bars) and 25 nM (red bars) of tau23 and its truncation (more ...)
We propose a model in which tau controls the balance of microtubule-dependent axonal transport in the neuron by locally modulating motor function. In a healthy neuron, tau can be distributed in a proximal-to-distal gradient (16, 17). Lower tau concentration at the cell body would allow kinesin to efficiently bind to microtubules and initiate anterograde transport of cargo; whereas, higher tau concentration at the synapse would facilitate cargo release (Fig. 4B). At the same time, dynein-driven retrograde transport from the distal axon would not be impeded due to dynein’s lower sensitivity to tau (Fig. 4B). Neurons can potentially fine-tune the occupancy of tau along axons by phosphorylation or dephosphorylation of sites within the microtubule-binding domain (18). Based on this model, perturbing tau distribution would predictably impair axonal transport. For example, in Alzheimer’s disease, tau accumulates in the somatodendritic compartment (19, 20); our model then predicts that kinesin-driven anterograde transport of new material to the axon terminal would be severely compromised, leading to neurodegeneration (1). The differential sensitivity of dynein and kinesin to tau thus provides a mechanism for spatiotemporal regulation of axonal transport.
Supplementary Material
MovieS1
MovieS10
MovieS2
MovieS3
MovieS4
MovieS5
MovieS6
MovieS7
MovieS8
MovieS9
Supplementary Data
Acknowledgments
We thank E. Mandelkow for the tau constructs, R. Kudaravalli for purified kinesin, S. Shah for data analysis, and M. Ostap and members of the Holzbaur and Goldman labs for helpful comments. This work was supported by NIH grants P01-AR-051174 to the Pennsylvania Muscle Institute and GM-48661 to EH, and NSF grant NSEC DMR04-25780 to the Penn Nano/Bio Interface Center.
1. Chevalier-Larsen E, Holzbaur EL. BioChim BioPhys Acta. 2006;1762:1094. [PubMed]
2. Vale RD. Cell. 2003;112:467. [PubMed]
3. Mallick R, Carter BC, Lex SA, King SJ, Gross SP. Nature. 2004;427:649. [PubMed]
4. Wang Z, Sheetz MP. Cell Struct Funct. 1999;24:373. [PubMed]
5. Ross JL, Wallace K, Shuman H, Goldman YE, Holzbaur ELF. Nat Cell Biol. 2006;8:562. [PubMed]
6. King SJ, Schroer TA. Nat Cell Biol. 2000;2:20. [PubMed]
7. Ebneth A, et al. J Cell Biol. 1998;143:777. [PMC free article] [PubMed]
8. Trinczek B, Ebneth A, Mandelkow E-M, Mandelkow E. J Cell Sci. 1999;112:2355. [PubMed]
9. Seitz A, et al. EMBO J. 2002;21:4896. [PubMed]
10. Vershinin M, Carter BC, Razafsky DS, King SJ, Gross SP. Proc Natl Acad Sci USA. 2007;104:87. [PubMed]
11. Andreadis A. Prog Mol Subcell Biol. 2006;44:89. [PubMed]
12. Ackmann M, Wiech H, Mandelkow E. J Biol Chem. 2000;275:30335. [PubMed]
13. Konzack S, Thies E, Marx A, Mandelkow E-M, Mandekow E. J Neurosci. 2007;27:9916. [PubMed]
14. Vale RD, et al. Nature. 1996;380:451. [PMC free article] [PubMed]
15. Gustke N, Trinczek B, Biernat J, Mandelkow E-M, Mandelkow E. Biochemistry. 1994;33:9511. [PubMed]
16. Kempf M, Clement A, Faissner A, Lee G, Brandt R. J Neurosci. 1996;16:5583. [PubMed]
17. Black MM, Slaughter T, Moshiach S, Obrocka M, Fischer I. J Neurosci. 1996;16:3601. [PubMed]
18. Ballatore C, Lee VM, Trojanowski JQ. Nat Rev Neurosci. 2007;9:663. [PubMed]
19. Khatoon S, Grundke-Iqbal I, Iqbal K. J Neurochem. 1992;59:750. [PubMed]
20. Braak H, Braak E, Mandelkow E-M. Acta Neuropathol. 1994;87:554. [PubMed]